PGI36 Relationship Between Clinical Severity and Health Related Quality of Life in Chronic Liver Diseases  by Scalone, L. et al.
this topics and its results express patients’ determination in looking for specialized
structures having funds for cures, which could lead to important internal and
external migration flows. Patients expect from EpaC to raise awareness in the
policy makers on the need for approval of the new DAAs and to bring on a campaign
of novel therapies equity of access with all Institution independently from the
severity of disease stage.
PGI33
ASSESSING GAS-RELATED SYMPTOMS AND THEIR ASSOCIATED IMPACT ON
THE DAILY LIFE OF THE GENERAL POPULATION AND IRRITABLE BOWEL
SYNDROME PATIENTS: INTERNATIONAL DEVELOPMENT OF A
QUESTIONNAIRE–QUALITATIVE STEPS
Tugaut B1, Guyonnet D2, Marrel A1, Arbuckle R3, Azpiroz F4, Whorwell P5, Chassany O6
1MAPI Consultancy, Lyon, France, 2Danone Research, Palaiseau, France, 3Adelphi Values,
Bollington, Cheshire, UK, 4Hospital General Vall d’Hebron, Barcelona, Spain, 5Wythenshawe
Hospital, Manchester, UK, 6Assistance Publique-Hopitaux de Paris & Denis-Diderot University,
Paris, France
OBJECTIVES: To develop a self-report questionnaire to evaluate gas-related symp-
toms (bloating, flatulence, belching, stomach rumbling and bad breath) and their
impact on daily life for Irritable Bowel Syndrome (IBS) patients and healthy subjects
complaining of gas-related symptoms. METHODS: A literature review and gastro-
enterologist interviews (n6) supported development of a preliminary conceptual
framework which was discussed with and validated by an international expert
committee. Then, semi-structured focus groups and face-to-face interviews with
IBS patients (n28) and healthy subjects (n27) complaining of gas-related symp-
toms were conducted in France, Spain and the UK. Qualitative analysis confirmed
the questionnaire conceptual framework, which was finalized with the expert
committee. Questionnaire items were generated simultaneously in French, Span-
ish and UK English, with item content based on subjects’ quotations. Iterative
rounds of cognitive debriefing interviews with IBS patients (n15) and healthy
subjects (n15) were subsequently conducted to assess questionnaire understand-
ing, acceptability and content validity across countries. RESULTS: Eight gas-related
symptoms (bloated feeling, distension, flatulence, and odorous flatulence, sensa-
tion of difficult gas evacuation, stomach rumbling, belching and bad breath) were
identified and described by the subjects in terms of severity and/or duration. Qual-
ity of life domains impacted by these symptoms were: emotional, clothing, diet,
cognitive function, physical appearance, social life, work life, sleep, sexual life,
physical activity, activities of daily living and partner relationships. Both a 24-hour
recall symptom diary (18 items) and a 7-day recall impact questionnaire (26 items)
were generated supported by the qualitative findings. Comprehension testing to
confirm the relevance and understanding of the instruments is on-going.
CONCLUSIONS: The questionnaires were developed following a rigorous method-
ology based on comprehensive qualitative research. Both gas-related symptoms
and their associated impact are assessed in a manner appropriate for two popula-
tions. This makes it a unique tool to be included in clinical programs. The next step
is to perform psychometric validation.
PGI34
A PATIENT-REPORTED OUTCOME MODEL FOR CROHN’S DISEASE
Wilburn J1, Mckenna S1, Twiss J1, Ben-L’amri M1, Kemp K2, Campbell S2
1Galen Research Ltd, Manchester, Gtr Manchester, UK, 2Manchester Royal Infirmary, Manchester,
Gtr Manchester, UK
OBJECTIVES: Research into the impact of Crohn’s Disease (CD) and its treatment
on the patient is reliant on dated generic questionnaires of limited relevance.
These measures ask questions of limited relevance to the population and miss
crucial aspects of the illness experience. As part of a study to develop CD-
specific patient-reported outcome (PRO) measures, qualitative interviews were
conducted with CD patients in order to model the impact of the disease on the
patient. METHODS: Interviews were conducted with CD patients recruited from
out-patient clinics. The interviews, which took the form of focused conversa-
tions covering all aspects of the impact of CD and its treatment, were audio-
recorded. The interview transcripts were analysed to identify the symptoms,
activity limitations and QoL impairments resulting from CD. This analysis em-
ployed the WHO International Classification of Functioning, Disability and
Health (ICF) and the needs-based quality of life (QoL) model. RESULTS: Thirty
patients (60% female; aged 25-68; mean (SD): 47.9 (14.3) years) were interviewed.
Participants had a wide range of CD duration (2-40; mean (SD): 14.3 (13.4) years).
Nearly 3,000 statements relating to the impact of CD were identified. These fell
into 3 major categories; symptoms (including pain, fatigue and emotional im-
pairment), activity limitations (examples; walking, lifting and jobs around the
house) and QoL. Needs affected by CD included autonomy, preoccupation with
CD, self-consciousness and reduced socialisation. CONCLUSIONS: The findings
from the interviews indicate that CD has three major types of impact; symp-
toms, activity limitations and QoL. All three should be addressed in CD audit,
clinical trials and when evaluating clinical practice. Items generated from the
interviews will be used to form a new suite of PRO measures specific to CD.
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OBJECTIVES: Patients with hemophilia A and inhibitors are at high risk for severe
bleeding and progression of joint disease with consequent deterioration of their
health-related quality of life (HRQoL). The Pro-Feiba Study was designed to assess
clinical and quality of live outcomes comparing prophylaxis to on demand therapy.
METHODS:A prospective, randomized, crossover study (Pro-FEIBA Study) aimed to
evaluate safety, efficacy and HRQol of AICC for bleeding prophylaxis in hemophilia
A patients 2 years with high-responding inhibitors. The study compared 6
months of AICC prophylactically dosed at 85 U/kg15% on 3 non-consecutive days
per week with 6 months of on-demand therapy (85 U/kg15%). The 2 study periods
were separated by a 3-month washout (patients used on-demand therapy). Quality
of life in patients 14 years was assessed at the beginning and end of each study
period with 2 generic instruments: the Short-Form 36 (SF-36) and the EQ-5D.
RESULTS: Nineteen subjects, of 26 valid patients , were 14 years and potentially
evaluable for HR-QoL. Of these, 18 patients (mean age: 32.6 years; min-max: 16.1-
62.8) completed SF-36 and/or EQ-5D questionnaires at each time point. Sixteen
patients completed both the SF-36 and the EQ-5D at the beginning and end of each
study period, 1 patient completed only the SF-36, and 1 patient completed only the
EQ-5D. A comparison of the 2 periods showed a trend towards HRQoL improvement
favouring prophylaxis. Differences between the 2 study period for SF-36 physical
component summary (PCS) were statistically significant in “good responders”
(50% bleeding episodes reduction) (p0.018). PCS differences were statistically
significant in all evaluable subjects when measured before and after prophylaxis
(p0.047). The EQ-5D health profile showed an improvement trend toward
prophylaxis. CONCLUSIONS: AICC prophylaxis significantly improved HRQoL as
compared with episodic treatment. Larger cohorts and longer follow-up are neces-
sary to confirm these data.
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OBJECTIVES: To assess the relationship between the type of chronic liver diseases
(CLDs), clinical severity and patients’ HRQoL. METHODS: A naturalistic, multicen-
tre study has been conducting to identify and test quality of care indicators. Adult
CLDs patients (age18 years) have been enrolling at gastroenterology unit of 3
Italian hospitals. We are collecting socio-demographic, clinical and HRQoL data
with the EQ-5D-3L. Patients are sub-grouped according to CLD type and to clinical
severity using the modified Child-Turcotte-Pugh score: with this instrument, pa-
tients are classified as non-cirrhotic, early cirrhotic (class A), advanced cirrhotic
(classes B and C). We conducted Kruskall-Wallis tests to assess relationship be-
tween EQ-5D-VAS score and disease type or severity score. RESULTS: Results are
based on data from 2,221 patients (67% male, median age62 years), classified into
the following subgroups: HCV or HBV chronic hepatitis (36.0%), compensated cir-
rhosis (CC, 23.5%), hepatocellular carcinoma (HCC, 19.8%), decompensated cirrho-
sis (DC, 13.5%), patients in evaluation or listed for liver transplant (LT, 7.2%). Non-
cirrhotic patients (HCV or HBV chronic hepatitis) had significantly (p0.001) higher
median VAS (80) than patients with any other CLD types (70). In contrast, patients
listed for LT had the lowest (p0.05) median VAS (65) and the highest proportion of
patients (58.1%) in Child class B-C. DC patients had a median VAS not significantly
different from that of HCC or CC patients (70 versus 70 and 73, respectively). On the
other hand, DC patients in child class A showed a significantly (p0.05) higher
median VAS (72.5) than HCC and CC patients in class B-C, who had a median VAS of
70 and 60, respectively. CONCLUSIONS: HRQoL of CLDs patients is significantly
related with the Child-Turcotte-Pugh severity score. These results could be useful
to understand the impact of the disease severity on patients’ HRQoL and guide
some decisions in clinical care.
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OBJECTIVES: Crohn’s disease is a chronic inflammatory bowel disease. Severe
Crohn’s disease management includes anti-Tumor Necrosis Factor (anti-TNF)
drugs differing from treatments used in early stages in terms of efficacy, safety and
convenience. To understand how specificities of anti-TNF treatments are per-
ceived by patients, the Satisfaction for Patients in Crohn’s disease (SPACE) ques-
tionnaire was developed to measure satisfaction with anti-TNF treatment in pa-
tients with severe Crohn’s disease. The study objectives were to finalise and
psychometrically validate the SPACE questionnaire. METHODS: An observational,
longitudinal, multicentre study was conducted in patients with severe, active
Crohn’s disease for which anti-TNF therapy was indicated. The 62-item pilot ver-
sion of the SPACE questionnaire was completed by patients at inclusion, 12 and 13
weeks after first anti-TNF injection. The final structure (i.e. grouping of items into
dimensions) was defined using multitrait and regression analyses. Psychometric
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